Ditch Labs Appoints Moishe Liberman, MD, PhD, FACS, FRCSC, as Chief Medical Officer
MONTREAL, QC/March 23, 2022 – Ditch Labs, Inc. is honored to appoint Dr. Moishe Liberman as Chief Medical Officer (CMO). Dr. Liberman is a minimally invasive thoracic surgeon trained at Harvard University who has run over 40 clinical trials at the CHUM Research Center over the last 13 years in Thoracic Surgical Oncology.
“It is a pleasure to be joining Ditch Labs’ stellar team to participate in developing such an innovative and revolutionary system. Seeing firsthand the consequences of tobacco use and the unmet needs caused by the lack of effective treatments, I am deeply motivated to contribute to the new paradigm that Ditch is creating in smoking cessation.”
- Dr. Moishe Liberman, Chief Medical Officer at Ditch Labs
Some of the responsibilities assumed by Dr. Liberman will be strategic supervision of the company’s medical and clinical affairs, including aiding in recruitment of various partners, establishing the corporation’s scientific advisory board and key opinion leadership and supporting in the design, planning and execution of clinical trials.
“Since the beginning, one of Ditch’s missions is to bring together the brightest minds to solve the leading cause of preventable death. The appointment of Dr. Liberman as CMO marks an important step in building a solid executive team, bringing us closer to reaching our first clinical milestone by the end of the year.”
- Laurent Laferrière, Co-Founder and CEO at Ditch Labs
As Ditch prepares for its First In Human study, the company looks forward to working alongside such a renowned physician with direct access to valuable resources and patients in dire need of effective smoking cessation treatments.